TAUROURSODEOXYCHOLIC ACID Snonymy: TAUROURSODEOXYCHOLIC ACID, 3ALPHA,7BETA-DIHYDROXY-5BETA-CHOLAN-24-OIC ACID N-(2-SULFOETHYL)AMIDE, TAUROURSODESOXYCHOLIC ACID,2-[[(4R)-4-[(3R,5S,7S,8R,9S,10S,13R,14S,17R)-3,7-dihydroxy-10, 13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoyl]amino] ethanesulfonic acid, TUDCA; 3alpha,7beta-Dihydroxy-5beta-cholanoyltaurine; UR 906; Ursodeoxycholyltaurine CAS.:14605-22-2 CB No.:CB0404332 M.F.:C26H45NO6S M.W.:499.7 M.P.:173-175°C Refractive Index:46°(C=1, EtOH) WGK Germany:2 RTECS:KI7372500 Tauroursodeoxycholic acid (TUDCA) is an ambiphilic bile acid. It is the taurine conjugate form of ursodeoxycholic acid (UDCA). Humans are found to have trace amounts of TUDCA. However, bears contain large amounts of TUDCA in their bile; UDCA and conjugates comprise about 47% of the bile in American black bears and up to 76% in Asiatic bears.TUDCA has been used in ancient Asian pharmacopoeias for its supposed beneficial effects. UDCA is produced in several countries for the treatment of gallstones and liver cirrhosis. It is not approved by the Food and Drug Administration, in the U.S. while UDCA is approved in the United States for the treatment of primary biliary cirrhosis Ongoing research is finding TUDCA has diminishing apoptotic effects, helping with cardiac function, Huntington's disease, Parkinson's Disease, and stroke. Recently, TUDCA has been found to have protective effects in the eye, especially concerning retinal degenerative disorders.
